NCT05695391终止3 期
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures
Laboratoire français de Fractionnement et de Biotechnologies27 个研究点 分布在 7 个国家目标入组 2 人开始时间: 2024年6月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 27
- 主要终点
- proportion of successfully at 24 hours after surgery
研究概览
简要总结
This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Each patient must meet the following criteria to be enrolled in this study:
- •be male with a diagnosis of congenital hemophilia A or B of any severity
- •have one of the following:
- •current positive inhibitor test BU ≥5 (as confirmed at screening by the institutional lab) or history of high-responding inhibitors (BU ≥5) not further successfully treated by Immune Tolerance Induction OR
- •a condition precluding the use of FVIII or FIX products to treat or prevent bleeding such as a previous anamnestic response after exposure to factor concentrates or a previous failure to respond to FVIII or FIX concentrates
- •be ≥12 years to ≤65 years of age on the day of informed consent
- •be scheduled for an elective major surgical procedure as defined in the study protocol (see Table ''Definitions for the specific purpose of Study F7TG2202'')
- •have Hb ≥ 12 g/dL
- •be capable of understanding and willing to comply with the conditions of the protocol OR in the case of a patient under the age of legal majority, parent(s)/legal guardian(s) must be capable of understanding and willing to comply with the conditions of the protocol
- •have read, understood, and provided written informed consent (patient or parent(s)/legal guardian(s) if the patient is minor according to local regulation) and, where applicable according to local regulation, patient's assent if the patient is minor
排除标准
- •Patients who meet any of the following criteria will be excluded from the study.
- •have any coagulation disorder other than hemophilia A or B
- •be immunosuppressed (i.e. the patient should not be receiving systemic immunosuppressive medication; CD4+ cell counts at screening should be >200/μL)
- •known intolerance to EB or any of its excipients
- •currently receiving immune tolerance induction (ITI) therapy
- •have a known or suspected allergy or hypersensitivity to rabbits or rabbit proteins
- •have platelet count <100,000/μL
- •have received an investigational drug within 30 days or within 5 half-lives of that investigational drug, whichever is longer, of the planned first EB administration, or be expected to receive such drug during participation in this study. Patients who have received fitusiran in a clinical study may not participate in this clinical study for 6 months since the last dose and if they have an antithrombin III level not in the normal range at screening.
- •for patients using emicizumab, have received during the last 6 months or currently receiving a maintenance dosing regimen of emicizumab different from the indicated one ± 10% of approved dose), i.e. different from 1.5 mg/kg once weekly (±10%), 3 mg/kg (±10%) every two weeks or 6 mg/kg (±10%) every four weeks
- •for patients using emicizumab, currently be any plans, or notes in the patient's medical records that would suggest the need to increase or decrease emicizumab dosing due to antidrug antibodies (ADAs), reduced PK, or coagulation/safety-related issues (e.g. lack of response, or potential/actual thromboembolic concerns, etc)
- •have a clinically relevant hepatic (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] >3 times the upper limit of normal [ULN]) and/or renal impairment (creatinine >2 times the ULN)
- •have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, transient ischemic attacks, DVT, or PE) within 2 years prior to the planned first dose of LR769, uncontrolled arrhythmia, or current New York Heart Association (NYHA) functional classification score of stages II - IV
- •have an active malignancy (those with non-melanoma skin cancer are allowed)
- •have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, or interfere with the study participation or study outcome (e.g. chronic, unmanaged hepatitis infection)
- •be using aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), herbs, natural medications, or other drugs with platelet inhibitory properties within one week prior to surgery and for the duration of treatment with EB
- •have active gastric or duodenal ulcer disease
- •have received a FVII- or FVIIa-containing product (either plasma derived or recombinant) within 24 hours prior to administration of EB
- •have a contraindication to antifibrinolytics
- •have planned combined major surgeries at the same time or have already been enrolled and treated for a previous elective major surgery in the same SCOPE HIM study
- •be administered pharmacologic thromboprophylaxis within 5 half-lives of that medication before surgery or for the duration of treatment with EB -
研究组 & 干预措施
Coagulation Factor VIIa (Recombinant)
Experimental
干预措施: Coagulation Factor VIIa (Recombinant) (Biological)
结局指标
主要结局
proportion of successfully at 24 hours after surgery
时间窗: at 24 hours after surgical wound closure
proportion of successfully treated major procedures defined by a good or excellent global hemostatic response.
proportion of successfully at wound closure
时间窗: at wound closure
proportion of successfully treated major procedures defined by a good or excellent global hemostatic response.
proportion of successfully at 120 hours after surgery
时间窗: at 120 hours after surgical wound closure
proportion of successfully treated major procedures defined by a good or excellent global hemostatic response.
Eptacog Beta (Activated) (EB) Effectiveness Based on Protocol's Aggregate Score
时间窗: From surgical wound closure until 120 hours after surgical wound closure
Successfully treated major procedures defined by a good or excellent global hemostatic response, based on an aggregate score from 3 timepoints (intra-operative, 24h post-operative, 120h post-operative), each individual score depending on comparison between actual and preliminary-communicated expected blood loss and transfusions for a similar patient without bleeding disorder undergoing the same surgical procedure, but also on the use or not of IMP extra-doses or of rescue therapy.
次要结局
未报告次要终点
研究者
研究点 (27)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and DyslipidemiaDyslipidemiasHypertensionNCT04074551Hanmi Pharmaceutical Company Limited145
进行中（未招募）
3 期
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)Bladder Carcinoma in Situ (CIS)NCT05024773Fidia Farmaceutici s.p.a.130
进行中（未招募）
3 期
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaNCT06206733AskGene Pharma, Inc.780
招募中
3 期
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue SarcomaSoft Tissue SarcomaNCT04650984Philogen S.p.A.102
进行中（未招募）
3 期
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerUrothelial CarcinomaUrothelial Carcinoma BladderBladder CancerNCT05243550UroGen Pharma Ltd.240